Camino Pharma LLC

San Diego, CA

UEI
K6JUDA59JJ17
CAGE
78RU4
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
  • Limited Liability Company
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
7161 Rock Valley Ct, San Diego, CA 92122, USA
Founded
2014
Employees
1-10
Estimated annual revenue
$0-$1M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Biotechnology
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Preclinical validation of MGLU2 pams in alcohol use disorder U43AA031388 National Institute on Alcohol Abuse and Alcoholism (NIH) $3,937,688
Negative allosteric modulators (nams) of metabotropic glutamate receptors 2 & 3 (MGLU2/3) for the treatment of… R43MH122063 National Institute of Mental Health (NIH) $1,725,909

Grant subawards

Prime recipient Prime award Amount Awarded
Sanford Burnham Prebys Medical Discovery Institute Under the stated goals for Specific Aim 2, in Year 3, Camino Pharma will develop the Phase 2 clinical protocol and submit it to the FDA for feedback. In… U01DA057847 $946,474
Sanford Burnham Prebys Medical Discovery Institute As a subawardee, Camino Pharma, LLC will be involved in all aspects of the work described in this grant application. In particular, Camino Pharma will have… U01DA057847 $1,723,993
Sanford Burnham Prebys Medical Discovery Institute The aim of this R01 grant application is to evaluate our selective mGlu2 PAM (SBI-0801315) and dual acting mGlu2/3 PAMs (SBI-0799220) in validated efficacy… R01DA057120 $549,448
Sanford Burnham Prebys Medical Discovery Institute Camino Pharma, LLC will be involved in all aspects of the work described in this award. In particular, Camino Pharma will have direct responsibility to… R01DA057120 $456,965
Sanford Burnham Prebys Medical Discovery Institute The overall objective of this grant application is to advance SBP-9330 into the clinic and determine its safety, tolerability and pharmacokinetic (PK) profile… U01DA051077 $1,854,554

Similar vendors

Vendor Location Primary NAICS
Stress Therapeutics, Inc. UEI VLU8DHDM9JZ3 San Diego, CA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Amygdala Neurosciences, Inc. UEI QWM8J29664Y5 Palo Alto, CA —
Afasci, Inc. UEI UGMEBNM4WSL6 Burlingame, CA 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Epigen Biosciences Inc. UEI L1EDVCGK2327 San Diego, CA 325199 All Other Basic Organic Chemical Manufacturing
Epivario Inc. UEI M6ZTFQ3K1WT3 Philadelphia, PA 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Camino Pharma LLC is a San Diego based startup company focused on discovering and developing first in class therapies for patients suffering from cancer and CNS disorders. Through past federal grants, Camino Pharma has conducted preclinical research and development of novel compounds for the treatment of alcohol use disorder, depression, and pain disorders. As a prime grantee, Camino Pharma has received a cooperative agreement from the National Institute on Alcohol Abuse and Alcoholism to validate three metabotropic glutamate receptor compounds in rat models of alcohol self-administration and sleep disturbances. As a subrecipient on grants from the National Institute of Mental Health and other agencies, Camino Pharma has performed toxicology studies, pharmacological testing, and FDA regulatory filing activities to advance lead candidates targeting depression and substance use disorders.

Quick answers

Is Camino Pharma LLC registered in SAM.gov?

Yes. Camino Pharma LLC's SAM.gov registration is active through May 20, 2027.

What is Camino Pharma LLC's most recent federal award?

Camino Pharma LLC's most recent federal grant award is Preclinical validation of MGLU2 pams in alcohol use disorder (U43AA031388), from National Institute on Alcohol Abuse and Alcoholism (NIH), on September 20, 2023.

On GovTribe

See Camino Pharma LLC's full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login